Abivax Approaches Q2 2026 Maintenance Data Readout as Obefazimod Advances Across Two Inflammatory Indications
SHERIDAN, WYOMING - April 14, 2026 - Abivax, a clinical-stage biotechnology company built around immune regulation through microRNA biology, is approaching a pivotal inflection point as 44-week maintenance results for its lead candidate obefazimod in ulcerative colitis (UC) remain on track for Q2 2026. The company disclosed positive top-line results from 8-week induction trials in UC in July 2025, providing the near-term clinical validation that now underpins the ongoing maintenance phase. Concurrently, its ENHANCE-CD trial in Crohn's disease - patient enrollment for which was initiated in Q3 2024 - is expected to deliver 12-week induction data in the second half of 2026. The convergence of two substantial readouts in a single year makes 2026 a defining period for Abivax's clinical program and operational planning horizon.